• Publications
  • Influence
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
TLDR
In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI. Expand
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.
TLDR
The ability of dimethylfumarate to activate nuclear factor (erythroid-derived 2)-related factor 2 may offer a novel cytoprotective modality that further augments the natural antioxidant responses in multiple sclerosis tissue and is not yet targeted by other multiple sclerosis therapies. Expand
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system.
TLDR
Elevated interferon beta concentrations in the CNS, but not blood, of mice with experimental autoimmune encephalomyelitis, a model for CNS autoimmunity are demonstrated, indicating a distinct protective function of type I IFNs during autoimmune inflammation of the CNS. Expand
Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.
TLDR
Critically discuss models of experimental autoimmune encephalomyelitis that reproduce specific features of the histopathology and neurobiology of multiple sclerosis and their shortcomings as tools to investigate emerging therapeutic approaches. Expand
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
TLDR
Subcutaneous daclizumab high-yield process (HYP) administered every 4 weeks led to clinically important effects on multiple sclerosis disease activity during 1 year of treatment, and support the potential for dacluzumab HYP to offer an additional treatment option for relapsing-remitting disease. Expand
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
TLDR
Aiden Haghikia,* Stefanie Jörg, Alexander Duscha, Johannes Berg, Arndt Manzel, Anne Waschbisch, Anna Hammer, De-Hyung Lee, Caroline May, Nicola Wilck, Andras Balogh, Annika I. Grohme, Stefan Kempa, Jan Thöne, Seray Demir, Dominik N. Müller, Ralf Gold, and Ralf A.L. Expand
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.
TLDR
The role of IL-17 is crucially involved in the cytokine network as an effector cytokine in EAE and neutralization ofIL-17 with a monoclonal antibody also ameliorated the disease course. Expand
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
TLDR
With the development of a reliable and validated assay for detection of antibodies in patients with MS directed against JCV, it is now possible to identify persons who are carriers of JCV and the availability of this assay provides an additional option for risk stratification of PML in patients using or considering natalizumab therapy. Expand
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.
TLDR
These studies show that both in situ nick translation and in situ tailing are useful in detecting DNA fragmentation in cell suspensions and tissue sections and may help to define the molecular mechanisms leading to cell death in experimental conditions and eventually in human tissue. Expand
CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation
TLDR
A factor is identified that modulates, in an inflammatory environment, glial cell survival and is an outcome determinant of EAE, suggesting that endogenous CNTF may counterbalance this effect of TNF-α. Expand
...
1
2
3
4
5
...